Influenza typically strikes during the late fall through early spring. During these annual epidemics, rates of serious illness and death are highest among persons aged ≥65 years, children aged <2 years, and persons of any age who have medical conditions that place them at increased risk for complications from influenza. It is estimated that influenza killed an average of 23,607 persons annually over 31 seasons in the U.S., with the death toll ranging from 3,349 in 1986–87 to 48,614 in 2003–04. Influenza hospitalized an estimated 226,000 persons annually during 1979–2001. This report is your annual pre-season update on influenza.

**VACCINATION RECOMMENDATIONS FOR 2011–2012**

For the first time in recent memory, the Advisory Committee on Immunization Practices (ACIP) is not expanding its recommendations to include any new age groups: they already advise everyone ≥6 months of age without a contraindication to receive an influenza vaccination annually. That said, some patients are at higher risk than others, and ACIP continues to suggest that special efforts be made to vaccinate the following:

- Pregnant females
- Children 6 months through 4 years of age, and especially those 6–23 months of age
- Persons ≥50 years of age
- Persons of any age with underlying medical conditions

underscore, anyway

† Chronic pulmonary (including asthma), cardiovascular (except isolated hypertension), renal, hepatic, neurological, hematologic, or metabolic disorders (including diabetes mellitus); and immunosuppression (including that caused by medications or HIV).

EGG ALLERGY?

At its June 2011 meeting, ACIP adopted new recommendations that allow for influenza vaccination of many persons who report an allergy to eggs:

- If your patients reporting egg allergies can eat lightly cooked (e.g., scrambled) eggs without reaction, than they aren’t allergic to them. Vaccinate ‘em.
- If a patient reports having experienced severe symptoms after consuming eggs (e.g., cardiovascular changes, respiratory distress, gastrointestinal symptoms, or reactions requiring epinephrine or emergency medical attention) refer them for evaluation to a physician with expertise in management of allergic conditions. Vaccination of any person reporting egg allergy should be done in a setting where anaphylaxis is, should it ensue, could be immediately recognized and treated.
- If a patient’s egg allergy has caused only hives, trivalent inactivated vaccine (but not live, attenuated vaccine) can be administered; but observe the patient for at least 30 minutes following vaccination.
- A previous severe allergic reaction to influenza vaccine (whether or not egg protein is thought to be the causative component) is still a contraindication.

**VACCINE COMPOSITION**

The World Health Organization (WHO) recommended that the Northern Hemisphere’s 2011–2012 seasonal influenza vaccine contain the following vaccine viruses:

- A/California/7/2009 (H1N1)-like;
- A/Perth/16/2009 (H3N2)-like; and
- B/Brussels/60/2008-like viruses.

These are the same viruses that were selected for the Northern Hemisphere for the 2010–2011 influenza vaccine. It is uncommon for the same three strains to be chosen for the flu vaccine from one season to the next: in the 42 seasons since 1969, the viruses selected for inclusion in the flu vaccine have remained the same only eight times. Each time, CDC has stressed the importance of getting vaccinated each season. Why? Influenza is a contagious respiratory illness caused by influenza viruses. Influenza can be serious as a complication of influenza for persons such as older adults, young children, and people with certain chronic medical conditions. CDC recommends that everyone ≥6 months of age without a contraindication to influenza vaccine receive an influenza vaccine annually.

### Figure 1 Rates of influenza hospitalization by age group, Oregon, 2006–2008

Source: Oregon Emerging Infections Program

Hospitalization rates are for Clackamas, Multnomah, and Washington counties only.
If you need this material in an alternate format, call us at 971-673-1111.

If you would prefer to have your CD Summary delivered by e-mail, zap your request to cd.summary@state.or.us. Please include your full name and mailing address (not just your e-mail address), so that we can purge you from our print mailing list, thereby saving trees, taxpayer dollars, postal worker injuries, etc.

Influenza antibody titers wane to ~50% of their original levels 6 to 12 months after vaccination, so annual booster doses are needed for optimal protection in all populations.3,6

It takes about two weeks after vaccination for antibodies to develop. ACIP recommends vaccinating as soon as vaccine is available. Now is not too early.

NEW: INTRADERMAL VACCINE

Sanofi pasteur received approval in May for Fluzone® Intradermal (ID) vaccine, the first influenza vaccine approved for intradermal delivery. It is indicated for persons 18–64 years of age. Its microinjection system uses an ultra-thin needle 1.5 mm in length. In contrast to the preparation of Fluzone® used for IM administration, which contains 15 μg of hemagglutinin per strain of influenza in a 0.5-mL dose, Fluzone® ID contains 9 μg of hemagglutinin per strain in a 0.1-mL dose. In clinical trials, Fluzone® ID induced in recipients protective antibody titers against the vaccine strains as follows:7

- A/H3N2: 99.5%
- A/H1N1: 81%
- B: 76%

These response rates were similar to those induced by the traditional 15 μg/strain IM formulation. Because Fluzone® ID is injected into the skin, however, it produces more erythema, induration, swelling and pruritus. These side effects were generally mild to moderate in intensity and resolved in 3–7 days. Reports of pain, fever, myalgia and malaise were similar in the two groups. No severe sequelae from ID administration have been reported.

TRACKING IMMUNIZATIONS

To keep track of who’s already been vaccinated so as to avoid duplicate vaccination, we strongly encourage reporting all influenza vaccinations to Oregon’s “ALERT” Immunization Information System (ALERT IIS). Doses can be reported via ALERT’s web interface or through electronic transfer of data. Visit www.alertiis.org and click on the TRAINING link for training information; or call the ALERT Helpdesk with questions: 800-980-9431.

Influenza reporting, 2011–2012

Please report the following lab-confirmed influenza-related illnesses:
- Death of a child <18 years of age
- ICU admissions and deaths among pregnant and post-partum women positive for any strain of influenza
- Hospitalizations in the Portland metropolitan area (Multnomah, Clackamas, Washington counties)
- Any novel influenza virus

Please report any of these to Matt Laidler by phone (971-673-1111) or email: Matthew.Laidler@state.or.us.

AND FOR LOCAL NEWS...

To find out what is going on locally in terms of activity and circulating strains, check out the Acute and Communicable Disease Prevention program’s weekly edition of Flu Bites, (http://healthoregon.org/fludata) or sign up for e-mail delivery on the web site.

We are currently recruiting providers for the outpatient Influenza-Like Illness (ILI) Surveillance Network (ILINet). Participating providers are asked to report ILI illness to CDC weekly. Specimens from ILINet patients may also be tested at Oregon State Public Health Lab free of charge. Please e-mail Rachel.S.Linz@state.or.us if you’re interested in participating.

REFERENCES

If you need this material in an alternate format, call us at 971-673-1111.

If you would prefer to have your CD Summary delivered by e-mail, zap your request to cd.summary@state.or.us. Please include your full name and mailing address (not just your e-mail address), so that we can purge you from our print mailing list, thereby saving trees, taxpayer dollars, postal worker injuries, etc.